Pathology and Lab Medicine

Episodes 1-16 of 24

Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Project Oncology®
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
- Brian P. McDonough, MD, FAAFP
- Marie Wood, MD
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Project Oncology®
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
- Ryan Quigley
- Hallie Blevins, PhD.
- Marlene Mimi Maeusli, PhD.
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
- Balazs Halmos, MD, MS
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
- Balazs Halmos, MD, MS
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Clinician's Roundtable
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
- Ashley Baker, MSN, PMHNP
- Heather Allen, PhD
- Ran Li, PhD
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
CME/CE
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
- Fernando López-Ríos, MD, PhD
- Christian Rolfo, MD, PhD
- Charlie Gourley, MD, PhD
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits